New bipolar depression treatment misses the mark in recent study

Intra-Cellular双相抑郁症药物Lumateperona未达试验主要终点,股价下跌14%

2019-07-09 12:02:00 pharmamanufacturing

本文共367个字,阅读需1分钟

A new treatment being investigated for bipolar depression has failed to meet its main goal in a recent study.  The drug’s developer, Intra-Cellular Therapies, released the results of the study this week which showed that patients receiving the drug, lumateperona, as a stand-alone treatment did not show a significant improvement in symptoms compared to those taking a placebo.  The study included 554 patients and was at odds with a different global study which did show an improvement in the severity of depressive symptoms compared to a placebo.  Lumateperona is also being investigated as an add-on therapy to traditional bipolar treatments — lithium and valproate — and if the results are positive, the company could still pursue a marketing application for the drug.  Headquartered in New York City, Intra-Cellular specializes in central nervous system diseases. The company calls lumateperona a “first-in-class” molecule because it targets dopamine, glutamate and serotonin — three neurotransmitter pathways associated with severe mental illness. The company has also studied the drug as a treatment for schizophrenia.  Results from the most recent bipolar study sent shares for the company falling by 14%.
在最近的一项研究中,一种新的针对双相抑郁的治疗方法未能达到其主要目标。 该药物的开发人员,细胞内治疗,本周公布的研究结果表明,接受该药物的患者,作为一个独立的治疗,没有显示出明显改善的症状相比,采取安慰剂。 该研究包括554名患者,与另一项全球研究结果不一致,该研究显示,与安慰剂相比,抑郁症状的严重程度有所改善。 Luminateperona 也在被调查作为传统双极性疗法的附加疗法——锂和丙戊酸钠——如果结果是积极的,该公司仍可以继续寻求该药物的营销应用。 总部设在纽约市,细胞内专门研究中枢神经系统疾病。该公司称 luateperona 为“一流”分子,因为它的目标是多巴胺、谷氨酸和血清素——与严重精神疾病相关的三种神经递质途径。该公司还研究了该药物作为治疗精神分裂症的药物。 最近的两相研究结果显示,该公司股价下跌了14%。

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文